Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2020

View Archived Issues

Equine encephalitis' entry elucidated

Initiation of RHB-204 phase III trial as first-line treatment of nontuberculous mycobacteria disease

SPL-7013 demonstrates potent antiviral activity against human RSV

MD Anderson and Obsidian collaborate to advance novel cytoTIL therapy for solid tumors

EicOsis completes phase Ia single-ascending dose trial of EC-5026

Immunity stays strong in longest-term COVID study to date

Slowing cholera down protects survivors of infection

Abbisko Therapeutics patents ROR-gammaT agonists

Beijing Jialin Pharmaceutical discloses new SMARCA2-targeting compounds

AiCuris presents new HBV inhibitors

Genfleet Therapeutics synthesizes KRAS inhibitors

Initial phase I data presented for BMS-986253 plus nivolumab in advanced cancer

Early first-in-human data reported for AMG-404

GSK presents phase II data for linerixibat, a potential oral treatment for primary biliary cirrhosis

RAP-011: a sotatercept analogue active in in vivo models of PAH

First cohort dosed in Molecular Partners' phase I study of COVID-19 candidate MP-0420

Tebentafusp improves OS in phase III trial in metastatic uveal melanoma

Bio-Path studies BP-1002 in refractory or relapsed lymphoma and CLL

FDA issues EUA for Regeneron's casirivimab and imdevimab for mild to moderate COVID-19

Neglected tropical ecosystems: Coral reef denizen's microbiome yields candidate Candida fighters

Phase II dosing begins with brequinar to treat COVID-19

Pooled analysis shows AZD-1222 effective at preventing COVID-19

European Commission approves quadrivalent meningococcal conjugate vaccine MenQuadfi

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...